Searl gets DRAP approval for biosimilar drug

MG News | December 14, 2023 at 12:06 PM GMT+05:00

0:00

December 14, 2023 (MLN): The Searle Company Limited (PSX: SEARL) has received approval from the Drug Regulatory Authority of Pakistan (DRAP) for ADALIMUMAB, a biosimilar drug developed in collaboration with BioRay Biopharmaceuticals Co. Limited, China, the company's latest filing on the PSX showed today.

This marks the first locally manufactured Monoclonal antibody (mABs) in Pakistan, the notice reads.

The introduction of ADALIMUMAB to the market within the next 3-6 months is a strategic move aimed at providing high-quality, affordable biotechnology medicines to patients in Pakistan, it said.

The company said that this development aligns with its commitment to diversifying its product portfolio, thereby enhancing the quality of earnings and shareholders' value.

Copyright Mettis Link News

Related News

Name	Price/Vol	%Chg/NChg
KSE100	162,163.81 363.99M	-0.70% -1140.32
ALLSHR	98,789.32 1,004.87M	-0.60% -591.65
KSE30	49,418.59 142.52M	-0.85% -423.92
KMI30	235,592.79 87.24M	-1.05% -2511.37
KMIALLSHR	64,955.16 475.31M	-0.97% -635.78
BKTi	45,437.77 69.21M	-0.59% -267.52
OGTi	32,150.13 9.02M	-1.60% -521.10

Symbol	Bid/Ask	High/Low

Name	Last	High/Low	Chg/%Chg
BITCOIN FUTURES	114,490.00	114,535.00 114,225.00	-580.00 -0.50%
BRENT CRUDE	65.75	66.64 65.06	-0.19 -0.29%
RICHARDS BAY COAL MONTHLY	80.50	0.00 0.00	-1.00 -1.23%
ROTTERDAM COAL MONTHLY	92.50	92.50 92.50	0.35 0.38%
USD RBD PALM OLEIN	1,082.50	1,082.50 1,082.50	0.00 0.00%
CRUDE OIL - WTI	61.47	61.50 61.45	0.16 0.26%
SUGAR #11 WORLD	14.47	15.04 14.34	-0.50 -3.34%